Anacor Pharma (ANAC) Misses Q3 EPS by 11c

Anacor Pharma (NASDAQ: ANAC) reported Q3 EPS of ($0.37), $0.11 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $24.6 million versus the consensus estimate of $25.6 million.

Anacor expects to submit a New Drug Application for crisaborole topical ointment, 2%, to the U.S. Food and Drug Administration in the first quarter of 2016

For earnings history and earnings-related data on Anacor Pharma (ANAC) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
• Reading (RDI) Tops Q2 EPS by 4c